ARV-825 / Arvinas - LARVOL DELTA

A versatile self-adjuvanting macro-microporous ZIF-8@Mn MOF platform for efficient antigen capture and presentation to boost antitumor immunity. (PubMed, J Control Release) - "Here, we develop a novel ISTV platform (SOM-ZIF-8@Mn/ARV) integrating a specific ICD inducer (ARV-825), and a multifunctional antigen catcher (SOM-ZIF-8@Mn) to boost antitumor immunity...This ISTV platform triggers robust antitumor immunity and achieves significant tumor growth inhibition when combined with αPD-1 blockade. The SOM-ZIF-8@Mn/ARV platform represents a powerful and effective advancement in improving the antitumor immune efficiency of ISTVs, offering a straightforward approach to the challenges faced in tumor immunotherapy."

Journal • Oncology • Targeted Protein Degradation • BRD4 • CD8

Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance. (PubMed, Nat Aging) - "Imposing mitochondrial stress via metabolic workload enhanced the senolytic efficacies of ABT263 and ARV825 in vitro, and in mouse models, ketogenic diet adoption or SGLT2 inhibition similarly potentiated ABT263-induced and ARV825-induced senolysis, reducing metastasis and tumor growth. These findings suggest that mitochondrial quality control is a key determinant of resistance to ABT263-induced and ARV825-induced senolysis, providing a possible framework for rational combination senotherapies."

Journal • Oncology

Therapeutic Potential of Bovine Colostrum- and Milk-Derived Exosomes in Cancer Prevention and Treatment: Mechanisms, Evidence, and Future Perspectives. (PubMed, Pharmaceuticals (Basel)) - "ARV-825-CME formulations increased antitumor activity in some cancer types...However, significant challenges remain in terms of their large-scale isolation, load heterogeneity, and regulatory standardization. Consequently, BMEs represent a new generation of biogenic nanoplatforms at the intersection of nutrition, immunology, and oncology, paving the way for innovative therapeutic approaches."

Journal • Review • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy via improved tumor targeting and ECM remodeling. (PubMed, Mater Today Bio) - "ARV825, a BRD4-targeting PROTAC, exerts potent antitumor effects by degrading BRD4, thereby suppressing Bcl-2 and PD-L1 expression, inducing apoptosis, and enhancing T cell-mediated immunity...As a result, ARV@Gip exhibited superior antitumor efficacy through dual mechanisms, including enhanced apoptosis and immune activation, outperforming ARV@lip in both tumor models. Collectively, this GRh2-functionalized liposomal platform overcomes key pharmacological barriers by integrating enhanced tumor targeting, ECM modulation, and dual pro-apoptotic/immunostimulatory effects, offering a promising therapeutic strategy for breast cancer."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • BCL2 • BRD4 • SLC2A1

The Resistance Mechanism to BET-Protac in Multiple Myeloma (ASH 2023) - "AR1 and AR2 cells showed decreased sensitivity to ARV-825, MZ-1, OTX-015, I-BET151, Daunorubicin and Epirubicin...Combined use of ABCB1 inhibitors (verapamil, cyclosporin A, Elacridar) or knockout of ABCB1 could significantly reduce the IC50 of drug-resistant cells, increase the apoptosis rate after ARV-771 treatment, and increase the degradation of BRD4 and the down-regulation of c-Myc... Our results showed that BET-PROTAC resistance in MM cells wasindependent of β-catenin activation. The up-regulation of ABCB1 expression was the key mechanism mediating the resistance of myeloma cells to BET-PROTAC. C1orf112, CCDC167 and CRIP2 might be associated with drug resistance in myeloma and could affect prognosis, and their mechanisms in myeloma need to be further investigated."

Hematological Malignancies • Multiple Myeloma • Oncology • Targeted Protein Degradation • ABCB1 • BRD4 • MYC • TCF7

Proteolysis targeting chimeras as senolytics: An emerging senotherapy for combating aging. (PubMed, J Pharmacol Exp Ther) - "Recent efforts have led to the development of several senescence-targeting proteolysis targeting chimeras, including ARV825, PZ15227, 753B, Gal-ARV-771, and Gal-MS99, which exhibit selective senolytic activity and improved safety and efficacy profiles when compared with small molecule inhibitors...PROteolysis TArgeting Chimeras (PROTACs) that induce selective degradation of target proteins, are emerging as a promising therapeutic strategy to address this unmet medical need. Recently, PROTACs have been explored as novel senolytics-termed "SenoTACs," which display improved safety and efficacy in targeting senescent cells for fighting aging-related diseases."

Journal • Review • Oncology • Targeted Protein Degradation

Microfluidic-assisted preparation of ARV 825 and Osimertinib loaded liposomal formulation as a potential system for colorectal cancer therapy. (PubMed, Int J Pharm) - "3D printed T-junction chips could be a promising alternative for the preparation of liposomes. The microfluidic-assisted co-delivery of ARV and OSI in liposomal formulations represents a compelling approach to overcoming drug resistance and enhancing CRC therapy by concurrently targeting EGFR and BRD4."

Journal • Colorectal Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • BRD4

Effectiveness of PROTAC BET degraders ARV-825 and ARV-771 in combating chemoresistance in HNSCC (AACR-NCI-EORTC 2025) - "Previous studies in our lab displayed that cisplatin-induced senescent HN30 HNSCC cells are sensitized to cell death via ABT-263 (Navitoclax), a senolytic BCL-2/BCL-XL dual inhibitor. The BET degraders ARV-825 and ARV-771 successfully sensitized chemoresistant head and neck cancer cells to cisplatin treatment. This may be due to the downregulation of the proliferation and survival markers c-Myc and Survivin following BRD4 degradation. Increased gH2AX expression and downregulated RAD51 with ARV-825 treatment suggest that accumulated DNA damage may contribute to senescence and apoptosis induction due to impaired BRD4 function."

IO biomarker • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA5 • BCL2 • BCL2L1 • BIRC5 • BRD4 • MYC • RAD51

BRD4 Mediates Transforming Growth Factor-β-Induced Smooth Muscle Cell Differentiation from Mesenchymal Progenitor Cells. (PubMed, Int J Mol Sci) - "In addition, the BRD4 inhibitor JQ1 and degraders ARV-825 and dBET1 suppressed TGF-β-induced SMC marker gene expression. Interestingly, the knockdown of BRD4 also attenuated the induction of myocardin due to TGF-β in 10T1/2 cells. Taken together, this study demonstrates that BRD4 is a novel modulator for SMC differentiation from mesenchymal progenitor cells through the regulation of TAZ and myocardin."

Journal • BRD4 • SMAD3 • TAFAZZIN • TGFB1

Polymer-engineered PROTAC nanovehicles amplify synergistic effects with temozolomide by BRD4 degradation. (PubMed, Biomater Sci) - "Furthermore, the delivery of ARV-825 using NPs achieves synergistic anti-tumor effects with temozolomide (TMZ) in GBM cells. These findings validate nanovehicles as a strategic solution for PROTAC limitations and provide a blueprint for translating catalytic degradation into clinically viable therapies against GBM."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • Targeted Protein Degradation • BRD4

Oxygen-Generating Transdermal Nanoplatform Codelivering BRD4 Proteolysis-Targeting Chimera/Verteporfin/CaO2 Synergistically Remodels Immunosuppressive Melanoma Microenvironment to Potentiate Combination Immunotherapy. (PubMed, ACS Nano) - "Melanoma relapse and metastasis remain formidable clinical challenges, with the inadequate immunogenicity and highly immunosuppressive tumor microenvironment (ITME) presenting serious obstacles to current postsurgical immunotherapies. Moreover, ARV825 acts like a PD-L1 blocking agent, cooperatively inhibiting immune evasion and resistance. Notably, AV@LDL&CaO2 MNs achieved a 90.0% melanoma inhibition rate, and elicited robust systemic immune protection against recurrence and metastasis with low-dose administration and minimal toxicity, offering a self-managing and innovative photodynamic-epigenetic-metallo-immunotherapy strategy for efficient postoperative melanoma management."

Journal • Dyslipidemia • Gene Therapies • Melanoma • Oncology • Solid Tumor • Targeted Protein Degradation • BRD4

Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. (PubMed, Biochem Pharmacol) - "Referring to the design of ARV-825, ARV-771 and MZ1, two novel BRD4 PROTACs were rationally designed and prepared via connecting the pan-BET selective bromodomain inhibitor JQ1 and two universal E3 ligase ligands targeting Von Hippel-Lindau (VHL) and cereblon (CRBN), namely VHL-JQ1 and CRBN-JQ1. Furthermore, combination therapy studies revealed that VHL-Q1 exhibited antagonistic effects when combined with paclitaxel, while demonstrating synergistic effects with cisplatin in TNBC treatment. Overall, our findings highlight VHL-JQ1 as a promising chemical probe for investigating BRD4 biological functions and a potential therapeutic candidate for TNBC treatment."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • Triple Negative Breast Cancer • Von Hippel-Lindau Syndrome • BRD4 • CRBN • KRAS

Effectiveness of PROTAC BET Degraders in Combating Cisplatin Resistance in Head and Neck Cancer Cells. (PubMed, Int J Mol Sci) - "We have demonstrated that cisplatin-induced senescent HN30 HNSCC cells can be eliminated by ABT-263 (navitoclax), a BCL-2/BCL-XL inhibitor that has senolytic properties. ARV-825 treatment downregulated BRD4 and its downstream targets, c-Myc and Survivin, as well as decreased the expression of RAD51, a DNA repair marker. These results suggest that the BET degraders ARV-825 and ARV-771 may be effective in improving the response of chemoresistant head and neck cancer to cisplatin treatment."

IO biomarker • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Targeted Protein Degradation • BCL2 • BCL2L1 • BIRC5 • BRD4 • MYC • RAD51

Enhanced Efficacy and Targeted Delivery System of a pH-sensitive ARV-825 Nanomedicine for Glioblastoma Treatment (EACR 2025) - "This study demonstrates that PROTAC-based nanomedicine represents a promising approach for treating glioblastoma. Our ARV-825-loaded pH-sensitive PBLA-PEG micelles enhanced drug potency, improved tumor targeting, and extended survival in preclinical GBM models. This nanomedicine approach warrants further investigation for clinical translation."

Clinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • Targeted Protein Degradation

Roles of Brd4 in Vascular Smooth Muscle Cells: Implications for Aging and Vascular Dysfunction. (PubMed, Arterioscler Thromb Vasc Biol) - "Primary cell cultures were established using mouse aortic SMCs and treated with Brd4 inhibitor, ARV-825, or (+)-JQ1. Experiments in vitro with Brd4 KO SMCs demonstrated the potential role of impaired autophagy and depleted α-tubulin in mediating induction of senescence in SMCs. Brd4 depletion in SMCs induces senescence, prevents neointima formation, and exacerbates vascular aging, highlighting its crucial roles in vascular functions and diseases."

Journal • BRD4 • TUBA4A

Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy. (PubMed, Biomaterials) - "Herein, a nano-PROTAC formulation (ARV@PEG-ICG) consisting of a phototherapeutic agent named indocyanine green functionalized polyethylene glycol (PEG-ICG) and a BRD4 degrader (ARV-825) was fabricated for cancer photo-immunotherapy...The distant tumor growth can also be inhibited due to the activation of long-term immune response. Overall, the current study aims to combine typical PROTAC with functional nanomaterials to form nano-PROTAC with high performance for PROTAC delivery mediated cancer treatment."

Biomarker • IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • BCL2L1 • BRD4

Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma. (PubMed, Invest New Drugs) - "Notably, ARV-825 was more effective at downregulating c-Myc and BET protein levels than JQ1 in both in vitro and in vivo experiments. These evidences suggest that BET-PROTACs may offer a promising novel strategy for the clinical treatment of DLBCL."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • ANXA5 • MYC

Anti-tumor effects following BET inhibition in preclinical models of pediatric and AYA osteosarcoma (AACR 2025) - "Effect of BETi (AZD5153, BMS-986378, ZEN-3694) in clinical trials for pediatric and adult solid tumors were investigated...To interrogate mechanisms of action, RNA-seq analysis of BET/BRD4 inhibition via AZD5153, PROTAC (ARV-825), and BRD4 siRNA in OS cell lines revealed distinct and overlapping patterns of alterations in gene expression...At the transcript level, increased DHRS2 was evident with no changes in TMPRSS9. These data sets reveal the promise of BETi for treatment of OS PDX derived from treatment naïve patients some of which go on to relapse, and in OS PDX derived from metastatic sites."

Preclinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • BRD2 • BRD4 • DHRS2 • H2AX

Development and optimization of a high-throughput LC-MS/MS method for the simultaneous determination of Exatecan and its Cathepsin B-sensitive prodrug, and ARV-825 in rat plasma: Application to pharmacokinetic study. (PubMed, J Pharm Biomed Anal) - "The proposed robust and economical method will be an alternative bioanalytical procedure for Exatecan and ARV-825 in the future. What is more, the present work could provide a reference for the clinical combination of the two drugs."

Journal • PK/PD data • Preclinical • Oncology • Targeted Protein Degradation • CTSB

A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines. (PubMed, Mater Today Bio) - "The selected PROTAC drug (ARV-825) can specifically degrade BRD4 without harming immune cells...Together with the PD1 antibody, this further enhanced the anti-tumor response of the in situ tumor vaccine and reversed the suppressive immune microenvironment. This antigen capture system provides a novel strategy to improve the anti-tumor efficacy of in situ tumor vaccines."

IO biomarker • Journal • Melanoma • Oncology • Solid Tumor • Targeted Protein Degradation • BRD4 • GPX4

Targeting BRD4 ameliorates experimental emphysema by disrupting super-enhancer in polarized alveolar macrophage. (PubMed, Respir Res) - "This study suggested that downregulation of BRD4 might suppress airway inflammation and emphysema through disrupting the SEs of IRF4 and alveolar macrophages polarization, which might be a potential target of therapeutic intervention in COPD. A diagram of the mechanism by which BRD4 mediated super-enhancer of IRF4 in M2 AMs. Graphic illustration showed targeting BRD4 in M2 polarized AMs lead to the downregulation of MMP12 expression, resulting in the amelioration of experimental emphysema by disrupting the super-enhancer of IRF4."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Pulmonary Emphysema • Respiratory Diseases • BRD4 • IRF4

Construction of novel magnetic systems for cancer immunotherapy via cancer-immunity cycle circuits. (PubMed, J Control Release) - "MCM nanoparticles (magnetic nanoclusters coated with calcium-doped manganese carbonate) efficiently load the tumor-targeting drug PROTAC (ARV-825), enhancing its bioavailability, leading to specific degradation of BRD4 in tumor cells, and releasing a large number of tumor-associated antigens...Magnetic M-BMDCs introduced at the tumor site are attracted to these magnetized vaccines, resulting in a significant increase in antigen uptake and activation of DCs, significantly enhancing the tumor immune cycle. This co-administration strategy of magnetized vaccines and magnetized BMDCs provides a unique combination therapy for reversing immunosuppressive TEM and enhancing the efficacy of tumor immunotherapy."

Journal • Oncology • Targeted Protein Degradation • BRD4

Bromodomain-containing protein 4 Mediates TGF-β-induced Smooth Muscle Cell Differentiation (AHA 2024) - "Interestingly, the BRD4 inhibitor JQ1 and degrader ARV-825 effectively blocked the differentiation of 10T1/2 cells towards SMCs induced by TGF-β, as indicated by decreased induction of SMC markers such as SM22α and α-SMA. In addition, BRD4 mediates the binding between TAZ and Smad3 to regulate the SMC marker gene transcription. Take together, our findings suggest that BRD4 modulates TGF-β-induced SMC differentiation and might play a role in SMC differentiation-related vascular diseases."

Atherosclerosis • Cardiovascular • Dyslipidemia • Fibrosis • Hypertension • Immunology • Oncology • BRD4 • SMAD3 • TAFAZZIN • TGFB1

Liposomes-mediated enhanced antitumor effect of docetaxel with BRD4-PROTAC as synergist for breast cancer chemotherapy/immunotherapy. (PubMed, Int J Pharm) - "ARV825, a bromodomain-containing protein 4 (BRD4)-PROTAC, has demonstrated the capacity to enhance the antitumor effect of the classic chemotherapeutic agent docetaxel (DTX)...This, in turn, augmented the antitumor effect of DTX in vivo without undesired side effects. In conclusion, BRD4-PROTAC may serve as a promising synergistic agent alongside the conventional chemotherapeutic agent DTX, with liposomes functioning as effective co-delivery vehicles."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • BCL2 • BRD4 • PD-L1

BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu-Modified GSH-Responsive Nanoparticles. (PubMed, Adv Sci (Weinh)) - "ARV-825 may play a role in modulating drug resistance by degrading the BRD4 protein, thereby exerting anti-glioma effects. Furthermore, mechanistic exploration revealed that T+A@Glu-NPs degraded the BRD4 protein, leading to the downregulation of Notch1 gene transcription and the inhibition of the Notch1 signaling pathway, thereby augmenting the therapeutic efficacy of glioma chemotherapy. Taken together, the findings suggest that T+A@Glu-NPs represents a novel and promising therapeutic strategy for glioma chemotherapy."

Journal • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • BRD4 • NOTCH1